Surgical Site Infections Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Destiny Pharma plc, POLYPID, Exoxemis, Covira Surgical, Inc., Eupraxia Pharmaceuticals, Son

Surgical Site Infections Pipeline constitutes 5+ key companies continuously working towards developing 5+ Surgical Site Infections treatment therapies, analyzes DelveInsight.

Surgical Site Infections Overview:

A surgical site infection (SSI) is an infection that develops after a surgical procedure at the site where the surgery was performed. These infections can range from mild, affecting only the skin, to more severe cases involving deeper tissues, organs, or implanted materials. The CDC provides guidelines and tools to assist healthcare professionals in preventing SSIs and offers resources to help the public understand and minimize their risk.

Symptoms of a surgical site infection typically appear within 5 to 7 days after surgery but may develop up to three weeks later, particularly if a prosthetic implant is involved. Common signs include spreading redness (erythema), localized pain, pus or discharge from the wound, and persistent fever (pyrexia).

Request for a detailed insights report on Surgical Site Infections pipeline insights @ https://www.delveinsight.com/report-store/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Surgical Site Infections Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Surgical Site Infections Therapeutics Market.

Key Takeaways from the Surgical Site Infections Pipeline Report

DelveInsight's Surgical Site Infections pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Surgical Site Infections treatment.
Key Surgical Site Infections companies such as Destiny Pharma plc, POLYPID, Exoxemis, Covira Surgical, Inc., Eupraxia Pharmaceuticals, Sonoran Biosciences, and others are evaluating new drugs for Surgical Site Infections to improve the treatment landscape.
Promising Surgical Site Infections pipeline therapies in various stages of development include XF-73, D-PLEX100, and others.

Recent breakthroughs in the Surgical Site Infections Pipeline Segment:

In March 2025, PolyPid Ltd. announced the successful completion of patient enrollment for its SHIELD II Phase 3 trial. This study evaluates the efficacy of D-PLEX100, a novel therapy aimed at preventing SSIs in patients undergoing abdominal colorectal surgeries with large incisions.
A study published in March 2024 demonstrated that implementing a simple pre-surgical infection prevention protocol significantly reduced dangerous post-surgical infections, emphasizing the importance of standardized preventive measures in surgical settings.

Surgical Site Infections Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Surgical Site Infections Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Surgical Site Infections treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Surgical Site Infections market.

Download our free sample page report on Surgical Site Infections pipeline insights @ https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Surgical Site Infections Emerging Drugs

XF-73: Destiny Pharma plc
D-PLEX100: POLYPID

Surgical Site Infections Companies

More than five key companies are actively developing therapies for Surgical Site Infections (SSIs). Among them, POLYPID has a drug candidate currently in the most advanced stage of development, Phase III.

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Surgical Site Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Surgical Site Infections Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Surgical Site Infections Therapies and Key Companies: Surgical Site Infections Clinical Trials and advancements @ https://www.delveinsight.com/report-store/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Surgical Site Infections Pipeline Therapeutic Assessment
• Surgical Site Infections Assessment by Product Type
• Surgical Site Infections By Stage
• Surgical Site Infections Assessment by Route of Administration
• Surgical Site Infections Assessment by Molecule Type

Download Surgical Site Infections Sample report to know in detail about the Surgical Site Infections treatment market @ Surgical Site Infections Therapeutic Assessment @ https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Surgical Site Infections Current Treatment Patterns
4. Surgical Site Infections - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Surgical Site Infections Late-Stage Products (Phase-III)
7. Surgical Site Infections Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Surgical Site Infections Discontinued Products
13. Surgical Site Infections Product Profiles
14. Surgical Site Infections Key Companies
15. Surgical Site Infections Key Products
16. Dormant and Discontinued Products
17. Surgical Site Infections Unmet Needs
18. Surgical Site Infections Future Perspectives
19. Surgical Site Infections Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Surgical Site Infections Pipeline Reports Offerings: https://www.delveinsight.com/report-store/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.